Found: 41
Select item for more details and to access through your institution.
Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study.
- Published in:
- Breast Cancer Research & Treatment, 2022, v. 191, n. 2, p. 389, doi. 10.1007/s10549-021-06424-z
- By:
- Publication type:
- Article
Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval.
- Published in:
- Breast Cancer Research & Treatment, 2021, v. 187, n. 3, p. 883, doi. 10.1007/s10549-021-06132-8
- By:
- Publication type:
- Article
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 184, n. 1, p. 53, doi. 10.1007/s10549-020-05817-w
- By:
- Publication type:
- Article
Production of human monoclonal antibody in eggs of chimeric chickens.
- Published in:
- Nature Biotechnology, 2005, v. 23, n. 9, p. 1159, doi. 10.1038/nbt1132
- By:
- Publication type:
- Article
RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 3, p. 461, doi. 10.1007/s10637-018-0665-y
- By:
- Publication type:
- Article
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 627, doi. 10.1007/s10637-017-0444-1
- By:
- Publication type:
- Article
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 4, p. 471, doi. 10.1007/s10637-017-0427-2
- By:
- Publication type:
- Article
Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 3, p. 691, doi. 10.1007/s10637-015-0236-4
- By:
- Publication type:
- Article
Retrospective Analysis of Survival Improvement by Molecular Biomarker-Based Personalized Chemotherapy for Recurrent Ovarian Cancer.
- Published in:
- PLoS ONE, 2014, v. 9, n. 2, p. 1, doi. 10.1371/journal.pone.0086532
- By:
- Publication type:
- Article
An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer.
- Published in:
- BMC Genomics, 2015, v. 16, p. 1, doi. 10.1186/1471-2164-16-S12-S2
- By:
- Publication type:
- Article
Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer.
- Published in:
- Oncology (08909091), 2018, v. 32, n. 10, p. 513
- By:
- Publication type:
- Article
A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer.
- Published in:
- Oncology (08909091), 2018, v. 32, n. 6, p. 298
- By:
- Publication type:
- Article
Breast Cancer Following Radiation for Hodgkin Lymphoma: Clinical Scenarios and Risk-Reducing Strategies ...includes discussion.
- Published in:
- Oncology (08909091), 2016, v. 30, n. 12, p. 1063
- By:
- Publication type:
- Article
Early-Stage BRCA2-Linked Breast Cancer Diagnosed in the First Trimester of Pregnancy Associated With a Hypercoagulable State.
- Published in:
- 2009
- By:
- Publication type:
- Case Study
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00439-5
- By:
- Publication type:
- Article
A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors.
- Published in:
- Cancers, 2024, v. 16, n. 8, p. 1456, doi. 10.3390/cancers16081456
- By:
- Publication type:
- Article
First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors.
- Published in:
- Cancers, 2024, v. 16, n. 1, p. 91, doi. 10.3390/cancers16010091
- By:
- Publication type:
- Article
Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer.
- Published in:
- Cancers, 2020, v. 12, n. 3, p. 719, doi. 10.3390/cancers12030719
- By:
- Publication type:
- Article
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Germline transmission of genetically modified primordial germ cells.
- Published in:
- Nature, 2006, v. 441, n. 7094, p. 766, doi. 10.1038/nature04831
- By:
- Publication type:
- Article
Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 23, p. 8801, doi. 10.1002/cam4.3487
- By:
- Publication type:
- Article
WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2021.642328
- By:
- Publication type:
- Article
Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2021.640690
- By:
- Publication type:
- Article
Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy.
- Published in:
- Frontiers in Immunology, 2023, p. 01, doi. 10.3389/fimmu.2023.1260545
- By:
- Publication type:
- Article
Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema.
- Published in:
- Neuro-Oncology, 2014, v. 16, n. 7, p. 1006, doi. 10.1093/neuonc/not329
- By:
- Publication type:
- Article
Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers.
- Published in:
- Therapeutic Advances in Medical Oncology, 2014, v. 6, n. 3, p. 88, doi. 10.1177/1758834013519843
- By:
- Publication type:
- Article
Show me The Money! do Financial Rewards for Performance Enhance or Undermine The Satisfaction from Emotional Labor?
- Published in:
- Personnel Psychology, 2013, v. 66, n. 3, p. 569, doi. 10.1111/peps.12037
- By:
- Publication type:
- Article
A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignancies.
- Published in:
- 2022
- By:
- Publication type:
- journal article
A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 90, n. 1, p. 7, doi. 10.1007/s00280-022-04443-1
- By:
- Publication type:
- Article
A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers.
- Published in:
- 2021
- By:
- Publication type:
- journal article
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2− breast cancer.
- Published in:
- NPJ Breast Cancer, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41523-024-00697-5
- By:
- Publication type:
- Article
Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00544-z
- By:
- Publication type:
- Article
A Phase I Dose‐Escalation Study of Linsitinib (OSI‐906), a Small‐Molecule Dual Insulin‐Like Growth Factor‐1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer.
- Published in:
- Oncologist, 2018, v. 23, n. 12, p. 1409, doi. 10.1634/theoncologist.2018-0315
- By:
- Publication type:
- Article
Descriptive statistics are powerful tools for organizational research practitioners.
- Published in:
- Industrial & Organizational Psychology, 2021, v. 14, n. 4, p. 481, doi. 10.1017/iop.2021.116
- By:
- Publication type:
- Article
Survival and clinical outcomes of patients with ovarian cancer who were treated on phase 1 clinical trials.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Interactions with the public: Bridging job design and emotional labor perspectives.
- Published in:
- Journal of Organizational Behavior (John Wiley & Sons, Inc.), 2010, v. 31, n. 2/3, p. 338
- By:
- Publication type:
- Article
From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2013, v. 105, n. 19, p. 1441, doi. 10.1093/jnci/djt209
- By:
- Publication type:
- Article
Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.
- Published in:
- Breast Cancer Research, 2024, v. 26, n. 1, p. 1, doi. 10.1186/s13058-024-01799-5
- By:
- Publication type:
- Article
SIOP Premieres New Student Consulting Challenge.
- Published in:
- TIP: The Industrial-Organizational Psychologist, 2023, v. 61, n. 1, p. 1
- By:
- Publication type:
- Article